No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

After a 20% stock plunge, Denmark's prized drugmaker triggers fears over jobs, confidence, and consumer spending.

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...

A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month low.

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

A week on from increases in the cost of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), weight loss medication provider ...

Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered ...